[ad_1]
In Europe, there are at least 10 million doses of the Covid-19 vaccine ready. They will become 20 by the end of the year and of these, at least 3 are destined for Italy. Everything solved? No. Phase 3 of the trial, although at an advanced stage, is still ongoing.
Covid, 10 million doses
Covid, Di Maio: “Vaccine, the first doses before the end of the year”
Covid Italia, Pregliasco: at this rate, in 15-20 days we will have to close regional borders
Covid, direct: more than 20 thousand cases in France. In Britain another 13,900 infections. Alarm in Holland. Record in Germany
The authorization from the EMA (European Medicines Agency) is missing, but the “continuous review” has already started, that is, the “continuous review” with which the test data provided by the producers is examined. The vaccine we are talking about is the one conceived by the Jenner Institute in Oxford, developed thanks to the contribution of Irbm from Pomezia, and created together with the British-Swedish biopharmaceutical multinational AstraZeneca.
The filling is in Anagni, at the Sanofi factory. And the production, at risk because the doses will not be able to be used if there is the rejection of the CHMP (the EMA’s committee on medicines for men), has already started. The objective is to have a significant amount available in the event of success, given the extraordinary nature of the emergency. This is the vaccine in which Italy and Europe have invested the most and there are those who wait for the green light within a month. Chancellor Luigi Di Maio: «At the end of the year we will have the first doses of vaccine and from the beginning of 2021 we will start vaccinations. We must make the last sacrifices to have the first doses before the end of the year and go out with the vaccine. The EMA has also started the “continuous review” of another vaccine, BNT162b2, produced by BioNTech in collaboration with Pfizer. They explain to the EMA: “The CHMP decision to initiate the ‘progressive review’ of BNT162b2 is based on preliminary results from early, non-clinical trials in adults suggesting that the vaccine triggers the production of antibodies and T immune system, defenses ) that target the virus. Large-scale clinical trials are underway with several thousand people, the results of which will be available in the coming weeks and months. In Rome there is another vaccine in experimental phase, all Italian: the one produced by ReiThera, whose Human experimentation continues at Spallanzani and there is a lot of confidence in. Another Italian vaccine candidate is Takis’s. The race is now global: China is picking up speed, with four vaccines already in phase 3 of the trial.
CHINESE
Wu Guizhen, the chief biosafety expert at the Chinese Center for Disease Control and Prevention, told CCTV that the vaccines “could be ready for general public use from November.” The administration for health workers, the military, the employees of the companies that produce vaccines has begun. The possibility of the United States announcing a green light for a vaccine before the US elections seems to have disappeared: Moderna, the company with one of the most advanced projects, has announced that it will not be able to apply for authorization before the end of November. Upmc, the University of Pittsburgh also present in Italy, is studying an antibody component of the drug Ab8 for possible therapeutic and prophylactic use against the coronavirus: given the microscopic size, it could also be administered by inhalation. Currently, 10 vaccines have reached phase 3 of the trial: the 4 Chinese (Sinovac, Bejing Institute-Sinopharm, Wuhan Institute-Sinopharm and Cansino Biological), Oxford-Irbm-AstraZeneca, the American from Moderna-Niaid, the Russian from Gamaleya, Novavax (United States), J&J (United States) and BionTech-Pfizer were developed between Germany and the United States together with the Chinese Fosun Pharma.
Last update: 01:07
© REPRODUCTION RESERVED
[ad_2]
